Efficacy of oral supplementation with branched-chain amino acid granules for patients with non-alcoholic fatty liver disease(NAFLD):pilot study

Efficacy of oral supplementation with branched-chain amino acid granules for patients with non-alcoholic fatty liver disease(NAFLD):pilot study - LIVACT NAFLD Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007260

Enrollment

Registered

2012-02-10

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease

Interventions

Branched-chain amino acid granules

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. BMI>25 kg/m2 2. Patient with fatty liver. 3. Obesty, Metabolic syndrome, Diabetes mellitus, Hypertension, dyslipidemia 4. HBs antigen negative, HCV antibody negative, Antinuclear antibody negative, Antimitochondrial antibody negative 5. Alcohol intake(ethanol)<=20g/day

Exclusion criteria

Exclusion criteria: 1. Subjects with a history of oral branched-chain amino acid granule use within 6 months 2. Patients with branched-chain amino acid metabolism abnormality 3. Diabetes patients treated with insulin 4. Patients with nonalcoholic steatohepatitis 5. Subjects who are judged for non-approved by investigator.

Design outcomes

Primary

Measure	Time frame
insulin resistance(HOMA-IR)	—

Secondary

Measure	Time frame
thioredoxin, oxidative stress	—

Countries

Japan

Contacts

Public ContactRyujin Endo

Iwate Medical University Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine

019-651-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026